The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.
Peter Andrew Kaufman
Consultant or Advisory Role - Eisai
Research Funding - Eisai
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche
Ahmad Awada
Consultant or Advisory Role - Eisai
Louise Yelle
Research Funding - Eisai
Edith A. Perez
No relevant relationships to disclose
Jantien Wanders
Employment or Leadership Position - Eisai
Martin S. Olivo
Employment or Leadership Position - Eisai
Yi He
Employment or Leadership Position - Eisai
Corina Dutcus
Employment or Leadership Position - Eisai
Christopher Twelves
Consultant or Advisory Role - Eisai
Honoraria - Eisai